Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

2026 Narcolepsy Family Weekend Recap

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders

A Beginner’s Guide to Managing Heart Health and Narcolepsy

Saventic Care Survey

Join Us for April’s Brown Bag Webinar – Navigating Narcolepsy and Pregnancy

The Wilder-Addison Narcolepsy Function Scale (WANFS)

Share Your Experiences With Narcolepsy – Paid Online Survey

Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy